Lung Cancer: Management
- PMID: 29313655
Lung Cancer: Management
Abstract
Lung cancer management that is individualized for age, comorbidities, cancer type, cancer stage, and patient preference has long been a cornerstone of management. New to this realm of individualized management are the emerging biologic therapies, immunotherapies, and targeted therapies for non-small-cell lung cancer provided by advances in genetics and molecular medicine. These techniques have led to a new field of precision medicine based on the unique molecular characteristics of a specific patient and the specific cancer. However, standard management including surgery, chemotherapy, and radiation therapy remains the most common management options for stage I through III lung cancers. Advancements in precision medicine are most relevant to patients with stage IV (ie, metastatic) lung cancers. Functional patient assessment and pulmonary function testing are keys to preoperative assessment. Early palliative care and a minimally invasive approach to surgery should be considered in patients who can tolerate surgery.
Written permission from the American Academy of Family Physicians is required for reproduction of this material in whole or in part in any form or medium.
Similar articles
-
[Combined-modality therapy for lung cancer].Nihon Rinsho. 2010 Jun;68(6):1121-8. Nihon Rinsho. 2010. PMID: 20535966 Review. Japanese.
-
Treatment of lung cancer.Radiol Clin North Am. 2012 Sep;50(5):961-74. doi: 10.1016/j.rcl.2012.06.003. Radiol Clin North Am. 2012. PMID: 22974781 Review.
-
Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?Oncology (Williston Park). 2007 Feb;21(2):163-71; discussion 171, 174, 179-82. Oncology (Williston Park). 2007. PMID: 17396481 Review.
-
Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.J Thorac Cardiovasc Surg. 2004 Jan;127(1):108-13. doi: 10.1016/j.jtcvs.2003.07.027. J Thorac Cardiovasc Surg. 2004. PMID: 14752420
-
Recent clinical advances in lung cancer management.J Clin Oncol. 2014 Apr 1;32(10):973-82. doi: 10.1200/JCO.2013.53.1228. Epub 2014 Feb 24. J Clin Oncol. 2014. PMID: 24567433 Review.
Cited by
-
CircPTCH1 Promotes Migration in Lung Cancer by Regulating MYCN Expression Through miR-34c-5p.Onco Targets Ther. 2021 Sep 10;14:4779-4789. doi: 10.2147/OTT.S324015. eCollection 2021. Onco Targets Ther. 2021. PMID: 34531664 Free PMC article.
-
Overexpression of miR-518b in non-small cell lung cancer serves as a biomarker and facilitates tumor cell proliferation, migration and invasion.Oncol Lett. 2020 Aug;20(2):1213-1220. doi: 10.3892/ol.2020.11667. Epub 2020 May 22. Oncol Lett. 2020. PMID: 32724361 Free PMC article.
-
MicroRNA‑208a directly targets Src kinase signaling inhibitor 1 to facilitate cell proliferation and invasion in non‑small cell lung cancer.Mol Med Rep. 2019 Oct;20(4):3140-3148. doi: 10.3892/mmr.2019.10542. Epub 2019 Jul 31. Mol Med Rep. 2019. PMID: 31432113 Free PMC article.
-
PFN1 Knockdown Aggravates Mitophagy to Retard Lung Adenocarcinoma Initiation and M2 Macrophage Polarization.Mol Biotechnol. 2024 Aug 9. doi: 10.1007/s12033-024-01228-0. Online ahead of print. Mol Biotechnol. 2024. PMID: 39120820
-
The Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside.J Clin Med. 2024 Oct 16;13(20):6164. doi: 10.3390/jcm13206164. J Clin Med. 2024. PMID: 39458114 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical